1501 related articles for article (PubMed ID: 25282520)
1. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
4. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
5. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
[TBL] [Abstract][Full Text] [Related]
9. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
Koren MJ; Descamps O; Hata Y; Hengeveld EM; Hovingh GK; Ikonomidis I; Radu Juul Jensen MD; Langbakke IH; Martens FMAC; Søndergaard AL; Witkowski A; Koenig W
Lancet Diabetes Endocrinol; 2024 Mar; 12(3):174-183. PubMed ID: 38310920
[TBL] [Abstract][Full Text] [Related]
11. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
[TBL] [Abstract][Full Text] [Related]
12. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
13. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
15. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
[TBL] [Abstract][Full Text] [Related]
16. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
17. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.
Santos RD; Ruzza A; Hovingh GK; Stefanutti C; Mach F; Descamps OS; Bergeron J; Wang B; Bartuli A; Buonuomo PS; Greber-Platzer S; Luirink I; Bhatia AK; Raal FJ; Kastelein JJP; Wiegman A; Gaudet D
Lancet Diabetes Endocrinol; 2022 Oct; 10(10):732-740. PubMed ID: 36075246
[TBL] [Abstract][Full Text] [Related]
18. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
[TBL] [Abstract][Full Text] [Related]
19. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study.
Sjouke B; Langslet G; Ceska R; Nicholls SJ; Nissen SE; Öhlander M; Ladenson PW; Olsson AG; Hovingh GK; Kastelein JJ
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):455-63. PubMed ID: 24731671
[TBL] [Abstract][Full Text] [Related]
20. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
